Pauses

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial…

Rivian to prioritize its current consumer product development roadmap and manufacturing capacity expansion as well as its commercial business IRVINE, Calif.--(BUSINESS WIRE)--Electric vehicle manufacturer Rivian has today announced it…